Advertisement

Topics

Eculizumab Cuts Relapse Risk in Neuromyelitis Optica

10:30 EDT 8 May 2019 | MedPageToday

(MedPage Today) -- No significant between-group difference in measures of disability progression in placebo-controlled trial

Original Article: Eculizumab Cuts Relapse Risk in Neuromyelitis Optica

NEXT ARTICLE

More From BioPortfolio on "Eculizumab Cuts Relapse Risk in Neuromyelitis Optica"

Advertisement
Quick Search
Advertisement
Advertisement